ArticleCancer research communications2025

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Zahra Davoudi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.